ASAP Scoring System And Risk Table (ASS-RT)
All the patients were divided into two groups according to second prostate biopsy pathology result. Group 1 was descripted as a patients with benign pathology (Prostatitis or Benign Prostate Hyperplasia) while group 2 was patients with prostate cancer (PCa) in second prostate biopsy. We designed a scoring system and risk table for evaluation of patients with ASAP before the repeat biopsy (Table 1).
Four benchmarks were scored from 0 to 3 or 4 point in the scoring system and risk table. tPSA was scored from 1 to 3 point according to 0-<4, 4-10 and >10 ng/dl. f/tPSA was scored from 1 to 3 point according to <0.15, 0.15-0.25 and >0.25%. PSA-D was scored from 1 to 4 point according to <0.08, 0.08-0.129, 0.13-0.15 and >0.15 ng/dl/ml. PSAv was scored 0 or 1 point according to the decrease or increase of tPSA before second prostate biopsy. Total score of ASS-RT was from 3 to 11 point. Last, subsequent to all assessment, all patients were divided according to total score as low (3-5), intermediate (6-8) or high (9-11) risk.